Celldex Therapeutics, Inc. Logo

Email this page: News Release

Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Celldex Therapeutics, Inc. for any marketing purposes.

Send:       


 
This helps Celldex Therapeutics, Inc. prevent automated submissions.